Board of Directors
Guiding the growth of Endocyte
John C. Aplin, PhD
Dr. John C. Aplin has served as a member of our Board of Directors since 2003 and as chairman since May 2011. Dr. Aplin has served as general partner and managing director of CID Capital, a venture capital firm he joined in 1990, after previously serving as president and chief executive officer of the Fuller Brush Company, a supplier of consumer products. Dr. Aplin holds a BS in business administration from Drake University, a MA in industrial and labor relations and a PhD in business administration from the University of Iowa. Dr. Aplin is also a certified management consultant.
Colin Goddard, PhD
Chairman and Chief Executive Officer
Dr. Goddard joined our Board of Directors in 2013 and joined BlinkBio as an investor and executive chairman in 2011, assuming the CEO role following the Series B financing in 2012. From 1998 until its $4 billion acquisition by Astellas Pharma US, Inc. in 2010, Dr. Goddard was CEO of OSI Pharmaceuticals, Inc., a company he joined as a scientist in 1989. Dr. Goddard holds a BS in biochemistry from the University of York in York, United Kingdom, and a PhD in cancer pharmacology from Aston University in Birmingham, United Kingdom. Dr. Goddard serves on the boards of several public and private biotechnology companies and has been active in many organizations that promote the advancement of cancer treatment and awareness, science education, and the biotechnology industry.
Mr. Kozin joined Endocyte’s Board of Directors in 2012 and is currently a senior advisor to L.E.K. Consulting, a global strategy consulting firm. Having served as president of L.E.K.’s North American practice for 15 years, Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. He also has deep industry expertise advising biopharmaceutical, life sciences, and medical technology companies. Mr. Kozin also serves on the boards of UFP Technologies, Medical Simulation Corporation, CrunchTime! Information Systems, and DukeEngage. Mr. Kozin received his BA with distinction, Magna Cum Laude, in economics from Duke University. He was also awarded an MBA with distinction from The Wharton School, University of Pennsylvania.
Philip S. Low, PhD
Chief Science Officer
Dr. Philip S. Low is one of our founders and has served as our chief science officer since 1998 and as a member of our Board of Directors since 1995. Dr. Low has served on the faculty at Purdue University since August 1976, where he is currently the Ralph C. Corley Distinguished Professor of Chemistry. He holds a BS in chemistry from Brigham Young University and a PhD in biochemistry from the University of California, San Diego.
Co-founder and Former Chief Business Officer and Chief Financial Officer
Mr. Machado joined our Board of Directors in February 2018. Mr. Machado is a co-founder of Medivation, Inc., a biopharmaceutical company that was acquired by Pfizer, Inc. in 2016. Prior to his retirement in April 2014, Mr. Machado served as Medivation’s Chief Financial Officer since its inception in September 2003, and as its Chief Business Officer since December 2009. Prior to Medivation, Mr. Machado served as Vice President, Chief Financial Officer and General Counsel, and as Senior Vice President and Chief Financial Officer at ProDuct Health, Inc. He has served as a consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Mr. Machado currently serves on the board of directors of biopharmaceutical companies Adverum Biotechnologies, Inc., Chimerix, Inc., Scynexis, Inc., Roivant Sciences Ltd., and Armaron Bio Pty, Ltd., where he also serves as chair of the board. Mr. Machado holds a JD from Harvard Law School and a BA and BS in German and Economics from Santa Clara University.
Fred A. Middleton
Sanderling Venture Partners
Fred A. Middleton has served as a member of our board of directors since July 2001. Since 1987, Mr. Middleton has been a general partner and managing director of Sanderling Ventures, a biomedical venture capital firm. During the last 30 years, Mr. Middleton has served in a number of management roles and as a member of the board of directors for over 20 biomedical companies. Mr. Middleton currently serves as a director of Stereotaxis, a medical device company, and until recently as the Chairman of the Board of Pacira Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Middleton also serves on the board of directors of five other privately-held biomedical and biotechnology companies. From 1978 through 1984, he served as Vice president and Chief Financial Officer for Genentech, Inc. Mr. Middleton holds a BS in chemistry from the Massachusetts Institute of Technology and an MBA with distinction from Harvard Business School.
Lesley Russell, MBChB, MRCP
Former Chief Medical Officer
Innocoll Holdings plc
Dr. Russell joined the Endocyte Board of Directors in 2013 and previously served as chief medical officer of Innocoll Holdings plc. Prior to Innocoll, Dr. Russell served as chief operating officer for TetraLogic Pharmaceuticals where she advanced the company’s lead candidate into Phase 2 clinical trials in parallel with the company’s initial public offering. Prior to this role, Dr. Russell held senior executive research and development positions at a number of biopharmaceutical companies including Teva Pharmaceuticals, Cephalon, Inc., and US Bioscience/Medimmune Oncology. In these roles, she managed staff responsible for a variety of functions including regulatory strategy development, clinical research, medical affairs and data management. Dr. Russell held positions at Amgen, UK, Lilly Industries, UK, and US Bioscience, now acquired by MedImmune Oncology. Dr. Russell received an MBChB degree from the University of Edinburgh, Scotland. She is a member of the Royal College of Physicians, UK, and is registered with the General Medical Council, UK. She currently serves as a member of the board of directors of AMAG Pharmaceuticals, a company traded on NASDAQ.
Mike A. Sherman
Chief Executive Officer/President
Mike A. Sherman joined Endocyte in 2006 and was recently named Chief Executive Officer and President. Mr. Sherman previously served as Chief Operating Officer and Chief Financial Officer. Prior to joining Endocyte, Mr. Sherman served in various executive roles, most recently as vice president of finance and strategic planning of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth. Mr. Sherman serves as Vice Chair on the Board of Trustees for the Indianapolis Children’s Museum. He also served on the Board of Directors at Mead Johnson Nutrition.
Former President of Merck's Europe/Canada Region
Dawn Svoronos joined the Endocyte Board of Directors in May 2018. Ms. Svoronos has over 30 years of experience in the pharmaceutical industry, including extensive commercial work at Merck & Co., Inc., where she held roles of increasing seniority for 23 years, prior to her retirement in 2011 as President of Merck’s Europe/Canada region. Previously, Ms. Svoronos served at Merck as President of Canada, Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchises. Ms. Svoronos is currently the Chair of the Board of Directors for Theratechnologies Inc., a specialty pharmaceutical company that trades on the Toronto Stock Exchange. Ms. Svoronos also serves on the Boards of Xenon Pharmaceuticals Inc. and PTC Therapeutics. Ms. Svoronos is also a member of the Board of Agnovos Healthcare Company, a privately held organization in New York. Ms. Svoronos received a BA from Carleton University in Ottawa, Ontario, Canada.